Media

Media Contact National Headquarters Walmart & FAACT Take the Fear Out of Halloween Fun! FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal Epinephrine) Pulmonary-Allergy Drugs Advisory Committee Meeting DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut FAACT Partners with MenuTrinfo® FAACT Is Learning to Live in Empathy A Statement from the Food Allergy & Anaphylaxis Connection Team about Racism, Food Allergy Disparities, and Health Inequities FAACT, ACAAI, NPB Partner on Early Intro to Peanut Vitality Bowls Rallies Communities in Support of Food Allergy Awareness Global Parenting Expert, Jo Frost, Announced as National Spokesperson for FAACT and Will Raise Awareness Around Food Allergies FAACT CEO Hosts Healthline’s Patient Roundtable: Living with Severe Allergies New FAACT and ACAAI Campaign Seeks to Close the Gap on Food Allergy Diagnosis and Management Awareness FAACT CEO Inducted into NAPW VIP Professional Woman of the Year Circle FAACT CEO Named Among The 15 Most Imporant Moms In the Food Industry FAACT Reaches Clawson Public Schools in Michigan

May 10, 2023

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

DBV is advancing regulatory efforts for Viaskin Peanut in toddlers ages 1 – 3 years old with a confirmed peanut allergy, reinforcing the potential of a new food allergy treatment option for this community.

In this trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy for 12 months was superior to placebo in desensitizing children to peanuts and increasing the peanut dose that triggered allergic symptoms.

Visit DBV Technologies to read their full press release.

You may read the New England Journal of Medicine Publication here.

Media Contact:
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com